Sa1221 ENDOSCOPIC MOLECULAR IMAGING OF EARLY GASTRIC CANCER USING HUMAN HEAVY-CHAIN FERRITIN NANOPROBE UNDER CONFOCAL LASER ENDOMICROSCOPY

Yang Du,Kelong Fan,Hejun Zhang,Shigang Ding,Xiyun Yan,Jie Tian

DOI: https://doi.org/10.1016/j.gie.2018.04.1422

IF: 10.396

2018-01-01

Gastrointestinal Endoscopy

Abstract:Molecular imaging represents a powerful tool for the immediate diagnosis of early gastric cancers (EGCs). In this study, the human heavy-chain ferritin (HFn), which specifically recognizes tumor biomarker transferrin receptor-1 (TfR1), was labeled with fluorescent agents to enable real-time imaging by confocal laser endomicroscopy (CLE). : In vivo molecular imaging was performed in tumor-bearing mice from gastric cancer cell lines (BGC-823 and SGC-7901). Xenograft tumors were visualized in vivo first with a whole-body fluorescent imaging device and then by CLE using fluorescently labeled HFn-nanoprobe. Human EGC specimens were examined ex vivo by HFn-nanoprobe-based CLE. 1. Generation of the HFn-nanoprobe, and its specific conjunction with gastric cancer cell. We labeled the protein shell of HFn with a dye for ex vivo tumor-cell imaging, in vivo fluorescence molecular imaging, and ex vivo CLE imaging; and we bio-mimetically synthesized magneto-HFn nanoparticle (M-HFn) for tissue IHC staining. The protein shells of both dye-HFn and M-HFn nanoprobes presented a well-defined morphology and were monodisperse in size. Western blotting and FACS results showed the general expression of TfR1 in BGC-823 and SGC-7901 cells. After tumor cells incubated with FITC-HFn, FITC-HFn showed membranous and cytoplasmic staining patterns. 2. Macroscopic Fluorescence Detection of TfR1 in Mice. We used macroscopic whole-body fluorescence detection to examine tumor-targeting efficacy of HFn labeled with IRDye800CW-HFn in mice harboring BGC-823 and SGC-7901 cells. Both tumor models showed increased HFn-targeted imaging and specific fluorescence signals in the tumors 4 h after tail-vein injection of IRDye800CW-HFn and the signals were still detectable at 48 h after HFn administration. The results were verified by ex vivo bench-top fluorescence-microscopy imaging and M-HFn IHC staining of the tumor xenografts (Fig.1). 3. HFn Binding to Human EGC Tissues Ex Vivo. Twenty-two cases EGC specimens after endoscopic submucosal dissection were available. After the incubation with FITC-HFn on EGC specimens , all EGCs showed specific FITC-HFn signal (22/22), whereas noncancerous tissues exhibited no (21/22) or weak specific fluorescence (1/22) (P < 0.0001). There is negative correlation between degree of HFn fluorescence signal and degree of tumor differentiation. The results were verified by the IHC and bench-top fluorescence staining. Our results also showed FITC-HFn-CLE imaging provided high contrast between cancerous and noncancerous tissues (Fig.2). Our HFn-nanoprobe-based CLE method is a promising approach for detection of EGCs, and this TfR1-targeted molecular imaging increases the accuracy of EGC detection and enables the visualization of tumor margins and guiding endoscopic resection.Fig. 2FITC-HFn identifies EGC. In the white-light image, a tumor-lesion area (A) was confirmed through histological analysis; the area is shown as regions 1 and 2 (B). The FITC-HFn probe was topically applied onto the tumor specimen (C and D) for staining. Stereomicroscopy imaging revealed specific fluorescence was detected in the tumorous regions 1 and 2 after FITC-HFn staining (E and F). Under CLE, a specific signal was detected in cancerous lesions, and high-magnification imaging showed strong membranous and cytoplasmic staining (G and H). The results of the IHC and bench-top fluorescence staining of the targeted tissue were confirmed through H&E staining (I-K; red dashed line: diseased area).View Large Image Figure ViewerDownload Hi-res image Download (PPT)